Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections

Lisa Jarvis: The knockoff GLP-1 market is still the Wild West

Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market last week when it introduced a cheap, compounded version of Novo Nordisk’s new Wegovy pill.

Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of its blockbuster GLP-1 medication semaglutide. Novo Nordisk alleges in its lawsuit that Hims & Hers has infringed on its patent by selling compounded Ozempic and Wegovy…

Wegovy maker Novo Nordisk sues rival over 'knock-off' weight-loss drugs

Novo Nordisk says Hims & Hers' drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".

Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs

Novo Nordisk wants Hims & Hers to get theirs. On Monday, the Danish pharmaceutical giant made good on legal threats to sue the online telehealth provider, which has been mass marketing cheaper, unapproved copycat versions of its blockbuster Ozempic and Wegovy weight loss drugs. Throwing Their Weight Around Hims & Hers invited enough fury from pharma sector rivals to burn a week’s worth of calories last Thursday when it announced plans to sell a …

Novo Nordisk Sues Hims & Hers Over Ozempic Copycats as the Weight-Loss Drug Wars Escalate

The lawsuit is the latest in an escalating feud between the Danish pharmaceutical and telehealth company.

'Complete Sham:' Novo Nordisk Sues Hims & Hers

Novo Nordisk has taken its fight over weight-loss drugs to federal court, targeting telehealth company Hims & Hers over what it calls unauthorized copycats of Wegovy and Ozempic. In a lawsuit filed Monday, the Danish drugmaker asked a court to block Hims & Hers from selling compounded versions of its...